AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: To further strength our conclusion that propofol enhances BCR-ABL TKIs’ inhibitory effects in CML through Akt/mTOR suppression, we pharmacologically inhibited mTOR using rapamycin and investigated the combinatory effects of rapamycin and imatinib.